Business Description
Pfizer Inc
NAICS : 325412
SIC : 2834
ISIN : US7170811035
Share Class Description:
PFE: Ordinary SharesCompare
Compare
Traded in other countries / regions
PFE.USA0Q1N.UKPFE.CanadaPFE.GermanyPFIZ34.BrazilPFE.ArgentinaPFE.MexicoPFE.PeruPFE.ChilePFE.AustriaPFE_KZ.KazakhstanPFE.SwitzerlandPFEBC.BelgiumPFE.Sweden IPO Date
1951-06-22Description
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.69 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.66 | |||||
| Debt-to-EBITDA | 2.18 | |||||
| Interest Coverage | 16.18 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.7 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34.4 | |||||
| 3-Year EBITDA Growth Rate | 29.6 | |||||
| 3-Year EPS without NRI Growth Rate | 42.5 | |||||
| 3-Year FCF Growth Rate | 34.7 | |||||
| 3-Year Book Growth Rate | 14.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -8.48 | |||||
| Future 3-5Y Total Revenue Growth Rate | -12.22 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 68.72 | |||||
| 9-Day RSI | 55.72 | |||||
| 14-Day RSI | 49.14 | |||||
| 6-1 Month Momentum % | -13.47 | |||||
| 12-1 Month Momentum % | -18.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.12 | |||||
| Quick Ratio | 1.82 | |||||
| Cash Ratio | 1.29 | |||||
| Days Inventory | 149.46 | |||||
| Days Sales Outstanding | 60.61 | |||||
| Days Payable | 96.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.83 | |||||
| Dividend Payout Ratio | 0.43 | |||||
| 3-Year Dividend Growth Rate | 3.6 | |||||
| Forward Dividend Yield % | 4.86 | |||||
| 5-Year Yield-on-Cost % | 6.05 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | 1.86 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.42 | |||||
| Operating Margin % | 30.09 | |||||
| Net Margin % | 27.55 | |||||
| ROE % | 22.58 | |||||
| ROA % | 10.7 | |||||
| ROIC % | 13.17 | |||||
| ROC (Joel Greenblatt) % | 148.6 | |||||
| ROCE % | 15.17 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.02 | |||||
| Forward PE Ratio | 10.3 | |||||
| PE Ratio without NRI | 9.02 | |||||
| Shiller PE Ratio | 11.69 | |||||
| Price-to-Owner-Earnings | 15.31 | |||||
| PEG Ratio | 0.42 | |||||
| PS Ratio | 2.49 | |||||
| PB Ratio | 1.93 | |||||
| Price-to-Tangible-Book | 31.68 | |||||
| Price-to-Free-Cash-Flow | 18.26 | |||||
| Price-to-Operating-Cash-Flow | 13.36 | |||||
| EV-to-EBIT | 8.76 | |||||
| EV-to-Forward-EBIT | 10.23 | |||||
| EV-to-EBITDA | 7.08 | |||||
| EV-to-Forward-EBITDA | 8.79 | |||||
| EV-to-Revenue | 2.72 | |||||
| EV-to-Forward-Revenue | 3.2 | |||||
| EV-to-FCF | 19.89 | |||||
| Price-to-Projected-FCF | 0.59 | |||||
| Price-to-Median-PS-Value | 0.62 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.36 | |||||
| Price-to-Graham-Number | 3.56 | |||||
| Earnings Yield (Greenblatt) % | 11.42 | |||||
| Forward Rate of Return (Yacktman) % | 28.69 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:PFE
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pfizer Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 77,944 | ||
| EPS (TTM) ($) | 3.76 | ||
| Beta | 0.57 | ||
| Volatility % | 20.25 | ||
| 14-Day RSI | 49.14 | ||
| 14-Day ATR ($) | 0.68346 | ||
| 20-Day SMA ($) | 33.533 | ||
| 12-1 Month Momentum % | -18.94 | ||
| 52-Week Range ($) | 31.7744 - 54.93 | ||
| Shares Outstanding (Mil) | 5,645.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pfizer Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pfizer Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pfizer Inc Frequently Asked Questions
What is Pfizer Inc(PFE)'s stock price today?
The current price of PFE is $33.90. The 52 week high of PFE is $54.93 and 52 week low is $31.77.
When is next earnings date of Pfizer Inc(PFE)?
The next earnings date of Pfizer Inc(PFE) is 2023-11-01 Est..
Does Pfizer Inc(PFE) pay dividends? If so, how much?
The Dividend Yield %  of Pfizer Inc(PFE) is 4.83% (As of Today), Highest Dividend Payout Ratio of Pfizer Inc(PFE) was 2.13. The lowest was 0.29. And the median was 0.75. The  Forward Dividend Yield % of Pfizer Inc(PFE) is 4.86%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers